UroGen Pharma (URGN) Tops Q3 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. KLAC
9. BIIB
10. ETSY

Go back to UroGen Pharma (URGN) Tops Q3 EPS by 3c

UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

November 10, 2022 8:00 AM EST

Full enrollment of ENVISION Phase 3 pivotal trial with UGN-102 in low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) expected as soon as the end of November 2022; NDA submission anticipated in first half of 2024 Reported JELMYTO® net product revenue of $16.1 million, an increase of 41% from the same period last year FDA authorized extension of the in-use period for JELMYTO® admixture from 8 to 96 hours following reconstitution further simplifying workflow for urologists

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to... More